Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.52 USD | +1.19% | +20.72% | +78.43% |
Apr. 23 | Edgewise Therapeutics Secures Orphan Drug Designations for Sevasemten in EU | MT |
Apr. 22 | RBC Raises Price Target on Edgewise Therapeutics to $32 From $28, Keeps Outperform, Speculative Risk | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+78.43% | 1.82B | |
+25.69% | 47.86B | |
+46.90% | 41.42B | |
-3.46% | 40.66B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- EWTX Stock
- News Edgewise Therapeutics, Inc.
- Edgewise Therapeutics Secures Orphan Drug Designations for Sevasemten in EU